Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514693-47-01

Enrollment

183

Registered

2025-10-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR mutated locally advanced or metastatic non-small cell lung cancer

Brief summary

Progression-free survival (PFS)

Detailed description

Overall survival (OS), Patient reported toxicity of any grade (laboratory abnormalities excluded), Economic assessment, Quality of life, Cumulative incidence of central nervous system (CNS) metastases, Feasibility / medication adherence

Interventions

DRUGTAGRISSO 80 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS)	—

Secondary

Measure	Time frame
Overall survival (OS), Patient reported toxicity of any grade (laboratory abnormalities excluded), Economic assessment, Quality of life, Cumulative incidence of central nervous system (CNS) metastases, Feasibility / medication adherence	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026